Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 57 min ago
Peer-reviewedLicence not statedImmunotherapy

Beyond PD-L1: emerging clinical and molecular biomarkers of response to immune checkpoint inhibitors in non-small cell lung cancer

  • Calogera Claudia Spagnolo1
  • Irene Campo2
  • Elena Fassi3,4
  • Francesco Nucera5
  • Paolo Ruggeri5
  • Paola Muscolino2
  • Carla Infurna2
  • Antonio Ieni6
  • Vanesa Gregorc3
  • Chiara Lazzari3
  • Mariacarmela Santarpia7
7 affiliations
  1. 1Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy
  2. 2School of Specialization in Medical Oncology, Department of Human Pathology “G. Barresi”, University of Messina, Messina, Italy
  3. 3INOC – Istituto Nazionale Oncologico Candiolo, IRCCS, Candiolo (TO), Italy
  4. 4Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Ospedali Civili, Brescia, Italy
  5. 5Respiratory Medicine Unit, Department of Biomedical Sciences, Dentistry and Morphological and Functional Imaging, University of Messina, Messina, Italy
  6. 6Anatomic Pathology Unit, Department of Human Pathology in Adult and Developmental Age “Gaetano Barresi”, University of Messina, Messina, Italy
  7. 7Medical Oncology Unit, Department of Human Pathology of Adult and Childhood “Gaetano Barresi”, University of Messina, Messina, Italy
Read full textDOICite

Related

  1. The Dynamic Role of Liquid Biopsy in Patients with Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors: Emerging Opportunities and Clinical Challenges
    Tancredi Didier Bazan Russo, Valerio Gristina, Francesco Pepe +13
    CancersPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  2. Editorial: Predictive biomarkers to immune checkpoint inhibitors in lung cancer
    Alessandro Russo, Christian Rolfo, Mariacarmela Santarpia
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  3. Immune Checkpoint Inhibitors and Hypothyroidism: An Emerging Public Health Challenge Identified Through a Systematic Review of ClinicalTrials.gov.
    Jeffrey Wu, Xuetao Wu, Hong Ren
    CureusPeer-reviewedCC BYFull textOncologyEurope PMCPMC
  4. Commentary: Hemophagocytic lymphohistiocytosis induced by immune checkpoint inhibitors: observations and proposed clinical management
    Gauthier Coussement, Maxime Ilzkovitz, Loïc Baudelet +2
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyGeneral medicineCrossrefDOAJ
  5. Association of pre-existing cardiovascular disease with cardiovascular and clinical outcomes in patients receiving immune checkpoint inhibitors
    Lama Alfehaid, Ahmed S. Alanazi, Mansour Alomran +2
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref

Cite

BibTeXRIS
BibTeX
@article{spagnolo2026beyond,
  title = {{Beyond PD-L1: emerging clinical and molecular biomarkers of response to immune checkpoint inhibitors in non-small cell lung cancer}},
  author = {Calogera Claudia Spagnolo and Irene Campo and Elena Fassi and Francesco Nucera and Paolo Ruggeri and Paola Muscolino and Carla Infurna and Antonio Ieni and Vanesa Gregorc and Chiara Lazzari and Mariacarmela Santarpia},
  journal = {Immunotherapy},
  year = {2026},
  month = oct,
  doi = {10.1080/1750743x.2026.2738337},
  url = {https://doi.org/10.1080/1750743x.2026.2738337},
}
RIS
TY  - JOUR
TI  - Beyond PD-L1: emerging clinical and molecular biomarkers of response to immune checkpoint inhibitors in non-small cell lung cancer
AU  - Calogera Claudia Spagnolo
AU  - Irene Campo
AU  - Elena Fassi
AU  - Francesco Nucera
AU  - Paolo Ruggeri
AU  - Paola Muscolino
AU  - Carla Infurna
AU  - Antonio Ieni
AU  - Vanesa Gregorc
AU  - Chiara Lazzari
AU  - Mariacarmela Santarpia
PY  - 2026
DA  - 2026/10/01
JO  - Immunotherapy
DO  - 10.1080/1750743x.2026.2738337
UR  - https://doi.org/10.1080/1750743x.2026.2738337
SN  - 1750-743X
SN  - 1750-7448
ER  -